Drug intelligence / Profile preview

dexamethasone + tobramycin

Development stage
Phase 4
Lead developer
Santen Pharmaceutical
Modality
Small Molecules
Administration
Ophthalmic
01

Overview

Dexamethasone + tobramycin is a fixed-dose combination ophthalmic medication consisting of the synthetic corticosteroid dexamethasone and the aminoglycoside antibiotic tobramycin. This combination is indicated for steroid-responsive inflammatory ocular conditions where a bacterial infection exists or there is a high risk of infection. Dexamethasone provides potent anti-inflammatory action by inhibiting the release of inflammatory mediators and suppressing the immune response, while tobramycin offers broad-spectrum bactericidal activity against common ocular pathogens by inhibiting bacterial protein synthesis. In the context of the REPEX clinical trial conducted by Azienda USL Reggio Emilia - IRCCS, this combination was utilized as the standard postoperative treatment to manage inflammation and prevent infection in patients with pseudoexfoliation syndrome (PEX) undergoing cataract surgery.

Brand names
TobraDexTobradex ST
Other names
dexamethasone 0.1% and tobramycin 0.3% ophthalmic suspensiondexamethasone 0.1% plus tobramycin 0.3% ophthalmic solutionDexamethasone+Tobramycin eye drop
02

Targets

Bacterial RibosomeBacterial 50S ribosomal subunitGR (Glucocorticoid receptor)

Beyond the preview

Go deeper on dexamethasone + tobramycin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on dexamethasone + tobramycin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call